`The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1

被引:0
|
作者
Horakova, Magda [1 ,2 ]
Horak, Tomas [1 ,2 ]
Bednarik, Josef [1 ,2 ]
Vohanka, Stanislav [1 ,2 ]
机构
[1] Univ Hosp Brno, ERN EURO NMD Ctr, Dept Neurol, Brno, Czech Republic
[2] Masaryk Univ, Fac Med, Brno, Czech Republic
关键词
Myotonia; Myotonic dystrophy; Methylprednisolone; Corticosteroids; Muscle relaxation; Therapy; CHANNEL;
D O I
10.1016/j.nmd.2020.03.004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We report the case of a patient suffering from duplicity of myotonic dystrophy type 1 and ulcerative colitis whose treatment for ulcerative colitis included repeated administrations of descending doses of methylprednisolone and in whom we found an association between methylprednisolone dosing and cessation of myotonia. Myotonia severity was expressed as relaxation time after voluntary contraction and as a patient-reported outcome using the Czech version of the Myotonia Behavior Scale. The patient was being treated for a flare of ulcerative colitis, starting with 32 mg of methylprednisolone and reducing the dose by 4 mg a week. The symptoms of myotonia began to wear off three weeks after starting methylprednisolone and had totally disappeared by four weeks after starting methylprednisolone. The first symptoms of myotonia returned about a month after the last dose of methylprednisolone and reached a peak of severity more than two months after the final dose. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:427 / 430
页数:4
相关论文
共 50 条
  • [31] Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1
    Saponaro, AE
    Marini, MA
    Rossi, GC
    Casas, JG
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2006, 45 (01) : 87 - 88
  • [32] Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1
    Feng, Jessica
    LaChance, Avery
    Sinclair, David A.
    Asgari, Maryam M.
    BMJ CASE REPORTS, 2019, 12 (03)
  • [33] Dehydroepiandrosterone for myotonic dystrophy type 1
    Penisson-Besnier, I.
    Devillers, M.
    Porcher, R.
    Orlikowski, D.
    Doppler, V.
    Desnuelle, C.
    Ferrer, X.
    Bes, M. -C. A.
    Bouhour, F.
    Tranchant, C.
    Lagrange, E.
    Vershueren, A.
    Uzenot, D.
    Cintas, P.
    Sole, G.
    Hogrel, J. -Y.
    Laforet, P.
    Vial, C.
    Vila, A. L.
    Sacconi, S.
    Pouget, J.
    Eymard, B.
    Chevret, S.
    Annane, D.
    NEUROLOGY, 2008, 71 (06) : 407 - 412
  • [34] Dysmetria in Myotonic Dystrophy type 1
    Subramony, S.
    Yacoubi, B.
    Casamento-Moran, A.
    Lott, Donovan
    Christou, Evangelos
    NEUROLOGY, 2018, 90
  • [35] Neuroimaging in myotonic dystrophy type 1
    Donahue, Laurence A.
    Mangla, Rajiv
    Westesson, Per-Lennart
    NEUROLOGY, 2009, 73 (22) : 1931 - 1931
  • [36] Afterdischarges in myotonic dystrophy type 1
    Yang, Li
    Chen, Xiuying
    Wu, Rui
    NEUROLOGICAL SCIENCES, 2024, 45 (02) : 735 - 740
  • [37] Afterdischarges in myotonic dystrophy type 1
    Li Yang
    Xiuying Chen
    Rui Wu
    Neurological Sciences, 2024, 45 : 735 - 740
  • [38] Suxamethonium and myotonic dystrophy type 1
    Nivoche, Y.
    Bruneau, B.
    Dahmani, S.
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2012, 31 (06): : 571 - 571
  • [39] Teaching Video NeuroImages: Trapezius myotonia percussion sign in myotonic dystrophy type 2
    Johnson, Nicholas E.
    Heatwole, Chad R.
    NEUROLOGY, 2013, 80 (24) : E251 - E251
  • [40] EVOKED MYOTONIA CAN BE "DIALED-UP" BY INCREASING STIMULUS TRAIN LENGTH IN MYOTONIC DYSTROPHY TYPE 1
    Logigian, Eric L.
    Twydell, Paul
    Dilek, Nuran
    Martens, William B.
    Quinn, Chris
    Wiegner, Allen W.
    Heatwole, Chad R.
    Thornton, Charles A.
    Moxley, Richard T., III
    MUSCLE & NERVE, 2010, 41 (02) : 191 - 196